ArticleBMC pharmacology & toxicology2026
Compound 7 h exerts its anti-oncogenic effects on colorectal cancer cells by inducing death-receptor-mediated apoptosis, promoting DNA damage, and obstructing autophagic flux.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPrevious research described a catalyst-free, post-Ugi synthesis of two distinct series of highly substituted fused pyrazolo-pyrazines. One of these series demonstrated antitumor activity against colorectal cancer (CRC) cells. However, the precise mechanistic pathways remain poorly understood, particularly with respect to effects on autophagy regulation, DNA repair processes, and death-receptor-mediated extrinsic apoptosis.
methodsThe cytotoxic properties of compound 7 h were assessed through MTT and colony formation assays, while apoptosis was evaluated by flow cytometry and western blotting. Immunofluorescence, GFP-LC3 transfection and mCherry-GFP-LC3B transfection were performed to assess autophagic activity. Synergistic interactions between derivative 7 h and 5-fluorouracil (5-FU) were investigated to assess enhanced CRC chemosensitivity. Molecular docking simulations were conducted to predict the binding conformation of compound 7 h with its molecular target and to identify potential interaction sites contributing to its inhibitory activity.
resultsCompound 7 h exhibited significant cytotoxic effects, inhibiting the proliferation and growth of CRC cells in vitro. Mechanistic investigations demonstrated that the cytotoxic activity of compound 7 h was mediated by impeding autophagic flux, thereby inducing DNA damage, inhibiting DNA repair, and ultimately promoting death receptor (DR)-mediated extrinsic apoptosis in CRC cells. Furthermore, the combination of compound 7 h with 5-FU exhibited synergistic inhibition of CRC cell proliferation, suggesting that compound 7 h could enhance CRC sensitivity to 5-FU.
conclusionsOur results suggest that impaired autophagic flux progression following treatment with compound 7 h leads to DNA damage and death-receptor-mediated apoptosis, underscoring the potential of compound 7 h as a novel therapeutic approach for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.